Safety and Efficacy of Decentralized HCV Treatment vs Standard-of-Care in Rio de Janeiro (Brazil)
A legfontosabb adatok
- Ki végzi
- Oswaldo Cruz Foundation
- Hol
- Rio de Janeiro (Brazília)Mind a 2 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 4. fázis
- Résztvevők
- 30 000 fő, tervezett
- Kezdés
- 2022. júl. 4.
- Várható befejezés
- 2026. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó, 6 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- Specialist - Epclusa 400Mg-100Mg Tablet
- Non- specialist - Epclusa 400Mg-100Mg Tablet
- HCV Self-Testing kit (Ora-Quick HCV ST or Wond-Foo HCV ST)
- HCV Rapid Testing kit
- A regiszteradat frissítve
- 2026. augusztus 17.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults aged 18 to 79 who visit a basic health care unit in Rio de Janeiro, for hepatitis C screening. People found to have active hepatitis C can join a treatment study comparing care by family doctors with care by specialists.
- Életkor
- 18 to 79 years
- Nem
- All sexes
- A betegség stádiuma
- Screening part: anyone in the age range. Treatment part: active or long-term (chronic) hepatitis C. People with signs of advanced liver scarring that no longer works well cannot join.
- Korábbi kezelés
- Treatment part: people who regularly take medicines that may interact with SOF/VEL, or medicines that weaken the immune system, cannot join.
- Biomarker vagy leletérték
- Treatment part: a positive HCVab test and detectable HCV-RNA (the virus is found in the blood).
A részvétel fő kizáró okai
- An illness needing urgent treatment, or a sudden illness with fever such as COVID-19, Dengue, Zika or Chikungunya
- Pregnancy (positive urine test) or breastfeeding, for the treatment part
- Also having HBV (hepatitis B) or HIV, for the treatment part
- Active cancer, a solid organ transplant, or a severe sudden illness
- Fluid in the belly, liver-related confusion, or bleeding in the gut within the last 12 weeks
A regiszter feltételei, szó szerint
Mind a 13 feltétel megnézéseKevesebb
Ki vehet részt
- Age between 18-79 years-old
- Age between 18 and 79 years old
- Presence of active/chronic hepatitis C, defined by a positive HCVab test and detectable HCV-RNA
Ki nem vehet részt
- Regular use of medications with potential drug interactions or contraindication for co-administration with SOF/VEL
- Presence of a disease that need urgent/emergency treatment and/or acute febrile illness, such as COVID-19, Dengue, Zyca virus infection or Chikungunya
- Co-infection with HBV or HIV
- Presence of severe acute illness, active neoplasia, solid organ transplant, or use of immunosuppressive medications
- Presence of clinical signs of decompensated liver cirrhosis (ascites, hepatic encephalopathy, report of a recent episode of gastrointestinal bleeding within the last 12 weeks)
- Children and adolescents (< 18 years old)
- Lack of capacity to sign the informed consent or refuse to participate; Study II
- Pregnancy, defined by a positive β-HCG urinary test
- Lactating individuals
Egyéb feltételek
- Study I and Sub-Study
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 79 év között vagy?
Ez a vizsgálat jelenleg itt érhető el: Brazília.
- Evandro Chagas National Institute of Infectious DiseasesRio de Janeiro, BrazíliaContact: Hugo Perazzo, PhDRésztvevőt keres
- Hugo PerazzoRio de Janeiro, BrazíliaContact: Hugo Perazzo, PhDRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
Up to 650,000 people in Brazil are living with chronic hepatitis c virus (HCV) infection. Hepatitis C is a silent disease, and up to 20% of cases can progress to liver cirrhosis and its complications. Rapid tests for diagnosis of HCV infection and non-invasive methods for detecting liver cirrhosis are available in the Brazilian Public Health System. Additionally, safe and highly effective drugs (direct-acting antivirals, DAAs) have been delivered for free for hepatitis C treatment by the Brazilian Unified Health System (Sistema Único de Saúde, SUS) since 2015. Sustained virological response (SVR) rates with DAAs in studies conducted in Brazil and Latin America were higher than 90%. Despite the availability of rapid tests for early diagnosis and effective drugs, the HCV continuum of care remains deficient in Brazil. It is estimated that only 10% of individuals known to have hepatitis C achieve HCV cure (SVR). This is explained by multiple barriers from diagnosis to treatment access, such as low rates of population screening (HCVST are not available in Brazil) and few available slots in tertiary centers for hepatitis C treatment by specialists. International studies have described that SVR rates by simplified hepatitis C treatment performed by non-specialists in the Primary Care System were similar to those treated in tertiary centers by specialists (standard-of-care). However, the optimal strategy for managing hepatitis C within the Brazilian-SUS remains unclear.This project aims to evaluate the improve of the HCV continuum of care by a implementation of a test-and-treat strategy in the Primary Care System in Brazil. The project consists of two parallel studies (and a sub-study).
A teljes eredeti leírásKevesebb
The project consists of two parallel studies (and a sub-study). Study I is a population-based cross-sectional screening study using rapid tests to determine the prevalence of HCV infection in people attending a Basic Health Care Unit. The sub-study associated with Study I is a cross-sectional study to assess the usability of a self-test for the detection of HCV antibodies in oral fluid (participants included in Study I). Study II is a phase IV open-label randomized clinical trial to evaluate the non-inferiority of simplified and decentralized hepatitis C treatment ("Simplified-and-Decentralized (SD) HCV treatment"; experimental arm) compared to specialist reference treatment ("Standard-of-Care (SC) HCV treatment"; control arm) within the SUS.
A vizsgálat 6 csoportja
- Study INincs vizsgálati kezelés, összehasonlításként
Study I is a population-based cross-sectional screening study (n=30,000 individuals) using rapid tests to determine the prevalence of HCV infection in people attending a Basic Health Care Unit.
- Substudy INincs vizsgálati kezelés, összehasonlításként
The sub-study associated with Study I is a cross-sectional study to assess the usability of a self-test for the detection of HCV antibodies in oral fluid (n=1,500 participants included in Study I).
- Study II - SpecialistMár használt kezelés, összehasonlításként
HCV standard-of-care treatment"; control arm. Participants randomized for the Standard-of-Care HCV treatment arm will be referred for the usual treatment of hepatitis C by specialists (hepatologists and/or infectious disease specialists) at a tertiary center \[INI/FIOCRUZ or Hospital Universitário Clementino Fraga Filho (HUCFF/UFRJ)\]. Participants will be treated with the pan-genotypic therapeutic regimen "single-pill daily," at a fixed dose and duration: sofosbuvir/velpatasvir 400/100 mg (Epclusa, Gilead Sciences, USA) 1 tablet orally per day for 12 weeks.
Kezelés: Specialist - Epclusa 400Mg-100Mg Tablet
- Study II - Non SpecialistMár használt kezelés, összehasonlításként
Decentralized hepatitis C treatment ("DS HCV treatment"; experimental arm).Participants randomized for the "Decentralized-and-Simplified HCV treatment" (DS HCV treatment) arm will be referred for simplified treatment of chronic hepatitis C at the Primary Health Care unit where participants were included in Study I and are registered for care. The treatment will be conducted by a non-specialist physician (general practitioner or family doctor) after training provided by a specialist (hepatologist) on the treatment of patients with hepatitis C using DAAs. Participants will be treated with a pan-genotypic therapeutic regimen, a fixed-dose, single-pill daily: sofosbuvir/velpatasvir 400/100 mg (Epclusa, Gilead Sciences, USA), 1 tablet orally per day for 12 weeks.
Kezelés: Non- specialist - Epclusa 400Mg-100Mg Tablet
- Sub-Study III - HCV Self-testing ArmMár használt kezelés, összehasonlításként
People randomized for this arm will receive an HCV self-testing kit (oral fluid or blood-based) for HCV testing
Kezelés: HCV Self-Testing kit (Ora-Quick HCV ST or Wond-Foo HCV ST)
- Sub-Study III - Standard-of-care: Rapid HCV Testing ArmPlacebo, összehasonlításként
People randomized for this arm will receive a prescription for HCV testing
Kezelés: HCV Rapid Testing kit
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Randomized Open-label and Non-inferiority Clinical Trial to Evaluate the Safety, Adherence, and Cost-effectiveness of Simplified and Decentralized Hepatitis C Treatment in Primary Health Care Compared to Standard-of-care in the Brazilian Public Health System
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT06306300: ki vehet részt
- A regiszteradat frissítve
- 2026. augusztus 17.